clinical trial · NCT07268040
A Trial of SHR-7787 Injection Combined With Other Anti-tumor Drugs in Patients With Malignant Solid Tumors
Shanghai Hengrui Pharmaceutical Co., Ltd.·phase2·recruiting·n = 400
Malignant Solid TumorsSHR-7787 InjectionSHR-1316 InjectionSHR-4849 InjectionEtoposide injectionCarboplatin injectionCisplatin injectionBP102 Injection
brief summary
This study aims to evaluate the safety, tolerability and efficacy of SHR-7787 in combination with other anti-tumor drugs in patients with malignant solid tumors.
started
Dec 23, 2025
primary completion
Dec 1, 2028
completion
Dec 1, 2028
last updated
Jan 12, 2026
official title
A Multicenter, Open-label Phase II Clinical Study of SHR-7787 Combined With Other Antitumor Drugs in Patients With Advanced Solid Tumors
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol